Ashley F. Slagle, M.S., Ph.D.

Over 22 years of experience in pharmaceutical outcomes research and COA development. Provides strategic regulatory and scientific advice on endpoints and COAs, including patient-reported outcomes. Formerly with the FDA, worked across CDER review divisions advising on COA-related submissions and participating in drug approval and labeling decisions. Passionate about incorporating the patient voice into drug development.